Nwam LLC Acquires New Position in Edwards Lifesciences Co. (NYSE:EW)

Nwam LLC bought a new position in Edwards Lifesciences Co. (NYSE:EW) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,568 shares of the medical research company’s stock, valued at approximately $697,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD lifted its holdings in shares of Edwards Lifesciences by 57.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after purchasing an additional 2,390,137 shares during the last quarter. Swedbank AB acquired a new stake in Edwards Lifesciences in the first quarter worth $124,511,000. Bank of New York Mellon Corp lifted its stake in Edwards Lifesciences by 4.3% in the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after buying an additional 809,605 shares during the last quarter. AustralianSuper Pty Ltd boosted its holdings in shares of Edwards Lifesciences by 17.8% during the third quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after acquiring an additional 494,604 shares during the period. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund grew its position in shares of Edwards Lifesciences by 422.3% during the third quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 450,233 shares of the medical research company’s stock worth $29,711,000 after acquiring an additional 364,030 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 0.1 %

Shares of Edwards Lifesciences stock opened at $70.48 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The firm has a market capitalization of $41.57 billion, a PE ratio of 10.17, a price-to-earnings-growth ratio of 3.96 and a beta of 1.12. The stock’s fifty day moving average is $67.70 and its 200-day moving average is $75.66.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the firm earned $0.59 earnings per share. The business’s quarterly revenue was up 8.9% on a year-over-year basis. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on EW. JPMorgan Chase & Co. lifted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Finally, Royal Bank of Canada reduced their price target on Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and a consensus target price of $75.67.

Insider Activity at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,262,521.36. The trade was a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,000 shares of company stock worth $2,657,000. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.